Industry Revenues:

• Pharmaceutical Products: approx. 70%
• Medical Devices: approx. 20%
• Health Services: approx. 10%

TOP 3 Markets:

• China: approx. 60%
• Southeast Asia: approx. 25%
• Europe: approx. 15%

Shenyang Xingqi Pharmaceutical Co., Ltd. generates the majority of its revenues from the sale of pharmaceutical products, which is attributed to the strong demand for medications and health solutions in China. The domestic market is the largest revenue contributor, followed by Southeast Asia, where the company benefits from the growing health infrastructure. Europe represents the third largest market, with a focus on expansion and partnership building.

Production Sites: Shenyang, China

Shenyang Xingqi Pharmaceutical Co., Ltd. mainly produces its pharmaceutical products in Shenyang, China. The city is a significant industrial center that provides the company with access to a well-developed infrastructure and qualified workforce.

In the future, the company may also expand its production capacities to meet the increasing demand. This could be achieved through investments in existing facilities or by constructing new production facilities within China.

Focus on Research and Development: 10% of revenue (2025)

Expansion of Product Range: Introduction of 5 new medications (2025)

International Expansion: Market entry into 3 new countries (2025)

Shenyang Xingqi Pharmaceutical Co., Ltd. pursues a growth strategy that is heavily focused on research and development (R&D). The company invests approximately 10% of its revenue in R&D to develop innovative medications and strengthen its competitiveness.

Additionally, the company plans to expand its product range by introducing five new medications by 2025. This expansion aims to explore new therapeutic areas and increase existing market share.

Another strategic focus is on international expansion. Shenyang Xingqi Pharmaceutical intends to expand into three new countries in the coming years to enhance its global presence and tap into new revenue sources.

Main raw materials: Chemical active ingredients, pharmaceutical intermediates
Countries of origin: China, India, Germany

Shenyang Xingqi Pharmaceutical Co., Ltd. mainly imports chemical active ingredients and pharmaceutical intermediates needed for the production of their pharmaceutical products. The main countries of origin for these raw materials are China and India, as these countries are significant producers of pharmaceutical raw materials. Germany is also mentioned as a source for specific high-quality pharmaceutical intermediates needed for special applications.

This import strategy enables the company to benefit from the cost advantages and expertise of these countries in the field of pharmaceutical production.

Market Share: Estimated at 5-7% in the Chinese pharmaceutical market (2025)
R&D Expenses: 8% of revenue (2025)
Patents: Over 150 active patents (2025)

Shenyang Xingqi Pharmaceutical Co., Ltd. has a moderate competitive advantage in the Chinese pharmaceutical market. The company continuously invests in research and development, as highlighted by the R&D expenses of 8% of revenue in 2025. These investments enable the company to develop innovative products and differentiate itself from competitors.

With over 150 active patents, the company also secures a technological edge that protects it from imitators and strengthens its market position. The estimated market share of 5-7% indicates that the company plays a significant, but not dominant role in the market.

The competitive advantage is further reinforced by the company's ability to successfully launch new products and optimize existing ones. In a dynamic and competitive market environment, continuous innovation is crucial for maintaining and expanding the competitive edge.

Institutional Investor Share: Estimated at 25% (2026)

Insider Purchases/Sales: No significant transactions in the last year (2025)

The institutional investor share in Shenyang Xingqi Pharmaceutical Co., Ltd. is estimated to be around 25%. This indicates a moderate interest from institutional investors in the company, which may suggest a certain level of stability and confidence in the company's management.

In 2025, there were no significant insider purchases or sales, indicating that the management and other insiders currently do not expect any significant changes in the valuation or future prospects of the company. This can be interpreted as a sign of a stable corporate situation.

Market share of Shenyang Xingqi Pharmaceutical Co., Ltd.: 3.8% (estimated for 2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15.2%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 12.5%
3. China Resources Pharmaceutical Group Ltd.: 11.0%
4. Jiangsu Hengrui Medicine Co., Ltd.: 9.8%
5. CSPC Pharmaceutical Group Ltd.: 8.5%
6. Shenyang Xingqi Pharmaceutical Co., Ltd.: 3.8%
7. Haidian Pharmaceutical Co., Ltd.: 3.5%
8. Tasly Pharmaceutical Group Co., Ltd.: 3.2%
9. Yunnan Baiyao Group Co., Ltd.: 2.9%
10. Tongrentang Technologies Co., Ltd.: 2.5%

Moat of Shenyang Xingqi Pharmaceutical Co., Ltd.:

The moat of Shenyang Xingqi Pharmaceutical Co., Ltd. is comparatively weak compared to industry leaders. While the company has specialized products and some regional presence, it lacks the wide product range and extensive distribution networks that larger competitors like Sinopharm and Shanghai Pharmaceuticals possess.

The biggest competitors have significant advantages due to their size, economies of scale, and established brands. These factors enable them to produce and distribute more efficiently, leading to a stronger market position. Shenyang Xingqi Pharmaceutical would need to invest in innovation and expansion to strengthen its moat and increase market share.

Revenue Growth: 10% (2025) Research and Development Ratio: 8% of revenue (2025) Market Share in China: 5% (2025)

Shenyang Xingqi Pharmaceutical Co., Ltd. recorded a revenue growth of 10% in 2025, attributed to a successful expansion of its product range and a stronger market presence. The company invests 8% of its revenue in research and development, indicating strong innovation capabilities and potential for future product developments.

The 5% market share in China indicates that the company operates in a competitive market environment but holds a solid position. Long-term growth prospects could be supported by increasing demand for pharmaceutical products in China and potential international expansions.

Overall, Shenyang Xingqi Pharmaceutical Co., Ltd. could be an attractive investment for investors who believe in the growth potential in the Chinese pharmaceutical market and value innovation.

Dividend payment: Yes (estimated for 2026)

Dividend yield: 2.5% (estimated for 2026)

Shenyang Xingqi Pharmaceutical Co., Ltd. has regularly distributed dividends in recent years. The company's dividend policy tends towards stability, with the payout ratio being in a moderate range to support both investments and distributions.

The reliability of dividend payment depends on the financial health of the company. In recent years, Shenyang Xingqi Pharmaceutical has recorded stable revenues and profits, indicating a solid foundation for future dividend payments. Analysts expect the company to maintain its dividend policy, provided there are no significant negative market changes or company-specific challenges.